Blockade of TNF-α induces increased levels of BAFF via upregulation of type I IFNs and has been associated with development of anti-nuclear antibodies in up to 50% of patients with clinical SLE [37]. The gene discussed is TNF; the disease is systemic lupus erythematosus.